At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
ANC-501drug
Likely dose
ANC-501 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of ANC-501 in the Treatment of Adults With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating ANC-501 for Major Depressive Disorder. Completed, enrolled 15 participants across 8 sites.
Detailed Summary
A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartSep 2022
Primary CompletionAug 2023
Study CompletionOct 2023
TodayJul 2026
First PostedJun 30, 2022
Enrollment StartSep 19, 2022
Primary CompletionAug 14, 2023
Study CompletionOct 18, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.0 years ago
Interventions
ANC-501drug
Five 10 mg capsules per day